Quarterly report pursuant to Section 13 or 15(d)

License Agreement with Duke - Additional Information (Detail)

v3.24.3
License Agreement with Duke - Additional Information (Detail) - USD ($)
3 Months Ended 9 Months Ended
Mar. 03, 2023
Aug. 31, 2024
Nov. 30, 2023
Aug. 31, 2023
Aug. 31, 2024
Aug. 31, 2023
Nov. 30, 2021
Patent Option And Technology License Agreement [Line Items]              
Impairment of assets     $ 13,108,064        
Duke University [Member]              
Patent Option And Technology License Agreement [Line Items]              
Amount on excess damages         $ 100,000,000    
Milestone payments first phase III clinical trial $ 2,000,000            
Capitalized costs to obtain agreement             $ 15,372,382
Capitalized costs amortization period   16 years     16 years    
Amortization expense   $ 0   $ 240,193 $ 0 $ 720,580  
Duke University [Member] | Maximum [Member]              
Patent Option And Technology License Agreement [Line Items]              
Additional capital related to research   $ 350,000     $ 350,000    
Research Agreement [Member]              
Patent Option And Technology License Agreement [Line Items]              
Consideration payable for research $ 187,400